Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

MET amplification is a frequently observed genomic aberration in solid tumors. We conducted a phase I trial to evaluate dose-limiting toxicity (DLT) and recommended phase II dose (RP2D) for the combination therapy. The following dose levels were tested in this single-arm phase I study: docetaxel as...

Full description

Bibliographic Details
Main Authors: Seung Tae Kim, Sujin Lee, Minhwa Park, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Young Suk Park, Won Ki Kang, Esha A. Gangolli, Hyeongchan Shin, Kyoung-Mee Kim, Simon J. Hollingsworth, Peter G.S. Mortimer, Jeeyun Lee
Format: Article
Language:English
Published: Elsevier 2019-04-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S193652331830367X

Internet

http://www.sciencedirect.com/science/article/pii/S193652331830367X

Similar Items